Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.

ABSTRACT:

Context

Vasomotor symptoms (VMS) are common, bothersome, and can persist for years before and after menopause.

Objective

We aimed to assess efficacy/safety of fezolinetant for treatment of moderate to severe VMS associated with menopause.

Methods

In this double-blind, placebo-controlled, 12-week phase 3 trial with a 40-week active treatment extension (NCT04003142; SKYLIGHT 2), women aged 40 to 65 years with minimum average 7 moderate to severe VMS/day were randomized to 12 weeks of once-daily placebo, fezolinetant 30 mg, or fezolinetant 45 mg. Completers were rerandomized to fezolinetant 30/45 mg for 40 additional weeks. Coprimary efficacy endpoints were mean daily change from baseline to week 4 (W4) and W12 in VMS frequency and severity. Safety was also assessed.

SUBMITTER: Johnson KA 

PROVIDER: S-EPMC10348473 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature